首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   3896篇
  免费   441篇
  国内免费   83篇
耳鼻咽喉   14篇
儿科学   32篇
妇产科学   48篇
基础医学   450篇
口腔科学   141篇
临床医学   209篇
内科学   642篇
皮肤病学   50篇
神经病学   373篇
特种医学   119篇
外国民族医学   1篇
外科学   703篇
综合类   143篇
现状与发展   1篇
预防医学   96篇
眼科学   176篇
药学   157篇
  1篇
中国医学   40篇
肿瘤学   1024篇
  2024年   23篇
  2023年   103篇
  2022年   190篇
  2021年   258篇
  2020年   214篇
  2019年   197篇
  2018年   195篇
  2017年   192篇
  2016年   194篇
  2015年   240篇
  2014年   302篇
  2013年   285篇
  2012年   170篇
  2011年   204篇
  2010年   132篇
  2009年   170篇
  2008年   167篇
  2007年   155篇
  2006年   143篇
  2005年   106篇
  2004年   82篇
  2003年   94篇
  2002年   83篇
  2001年   82篇
  2000年   52篇
  1999年   30篇
  1998年   50篇
  1997年   46篇
  1996年   32篇
  1995年   35篇
  1994年   40篇
  1993年   31篇
  1992年   20篇
  1991年   15篇
  1990年   18篇
  1989年   12篇
  1988年   6篇
  1987年   11篇
  1986年   4篇
  1985年   6篇
  1984年   6篇
  1983年   9篇
  1982年   7篇
  1981年   4篇
  1980年   2篇
  1979年   1篇
  1977年   1篇
  1966年   1篇
排序方式: 共有4420条查询结果,搜索用时 14 毫秒
981.
982.
Objective: To evaluate the efficacy of percutaneous ethanol injection (PEI) in the adjuvant treatment of hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE) by primary end points of time to progress (TTP). Methods: The study population consisted of 73 consecutive patients with inoperable HCC (China Classification System IIN liB). Among them, 22 patients were treated with TACE and PEI (experimental group), and the rest 51 were treated only with TACE (control group), and then the time to progress (TTP) and overall survival (OS) of these two groups were analyzed. Results: The median TTP was 10 months [95% confidence interval (CI), 7.9-12.1 months] in experimental group and 6 months (95% CI, 4.7-7.3 months) in control group. The 3-month,6-month, and 1-year Progression Free Survival (PFS) rates were respectively 77.3%, 63.6%, and 48.1% in experimental group, and 76.5%, 42.15%, and 24.8% in control group. The TTP of experimental group was significantly longer than that of control group (P 〈 0.05). The median survival period was 17 months [95% confidence interval (CI), 11-23 months] of experimental group and 12 months (95% CI, 10-14 months) of control group (P 〉 0.05). Conclusion: Compared with single TACE, the combination of TACE and PEI can obviously postpone disease progress and prolong survival of HCC patients.  相似文献   
983.
BackgroundThe aim of this study was to provide a guidance for the management of neuroendocrine tumors (NETs) in clinical practice.Material and MethodsNominal group and Delphi techniques were used. A steering committee of 8 experts reviewed the current management of NETs, identified controversies and gaps, critically analyzed the available evidence, and formulated several guiding statements for clinicians. Subsequently, a panel of 26 experts, was selected to test agreement with the statements through 2 Delphi rounds. Items were scored on a 4-point Likert scale from 1 = totally agree to 4 = totally disagree. The agreement was considered if ≥75% of answers pertained to Categories 1 and 2 (consensus with the agreement) or Categories 3 and 4 (consensus with the disagreement).ResultsOverall, 132 statements were proposed, which incorporated the following areas: (1) overarching principles; (2) progression and treatment response criteria; (3) advanced gastro-enteric NETs; (4) advanced pancreatic NETs; (5) advanced NETs in other locations; (6) re-treatment with radioligand therapy (RLT); (7) neoadjuvant therapy. After 2 Delphi rounds, only 4 statements lacked a clear consensus. RLT was not only recommended in the sequencing of different NETs but also as neoadjuvant treatment, while several indications for retreatment with RLT were also established.ConclusionThis document sought to pull together the experts’ attitudes when dealing with different clinical scenarios of patients suffering from NETs, with RLT having a specific role where evidence-based data are limited.  相似文献   
984.
Wang GQ  Wei WQ  Zhang JH 《癌症》2007,26(11):1153-1156
背景与目的:未经治疗的晚期贲门腺癌患者的生存时间为8~9个月.本研究目的是观察未进行任何治疗的早期胃贲门腺癌的自然发展史.方法:1987年在食管癌高发现场,对细胞学诊断为鳞状细胞重度增生的851例进行了内镜复查,同时检查了贲门区粘膜,经活检病理确诊为贲门腺癌者共43例.包括晚期癌12例,早期癌31例.其中17例早期患者虽经多次劝说,仍因不同原因拒绝治疗,随诊观察14年,直至全部患者死亡.结果:随诊14年,17例早期贲门癌患者中,12例死于贲门腺癌,另外5例死于非癌疾病;生存5年以上者13例,5年自然生存率为76.47%(13/17),10年自然生存率为23.53%(4/17).结论:早期贲门癌发展到晚期是一个漫长的演进过程.这对早期诊断和选择治疗时机很有帮助.同时,如要精确评估早期癌治疗效果,宜充分考虑其自然史的因素.  相似文献   
985.
目的 探讨肺癌术后患者症状群对恐惧疾病进展水平的影响,为加强症状管理以减轻患者疾病恐惧感提供参考。方法 以便利抽样法选取228例原发性肺癌手术患者,采用一般资料问卷、恐惧疾病进展简化量表(FoP-Q-SF)、中文版安德森症状评估量表-肺癌特异性症状模块(MDASI-L)进行调查。结果 肺癌术后患者的恐惧疾病进展总分为(29.75±9.10)分,症状发生率前3位分别为疲乏(98.25%)、疼痛(97.81%)和咳嗽(95.61%),症状严重程度分别为疼痛[5.00(3.00,8.00)]、疲乏[5.00(3.00,7.00)]和睡眠不安[5.00(2.00,7.00)]。探索性因子分析得出3个症状群,分别为疾病行为-心理情感症状群、肺癌特异症状群、胃肠道-神经症状群。Spearman相关性分析结果显示,恐惧疾病进展总分及各维度得分与3个症状群呈正相关(rs=0.467~0.683,均P<0.05)。多元线性回归分析显示,疾病行为-心理情感症状群、肺癌特异症状群为患者恐惧疾病进展的影响因素(均P<0.05)。结论 肺癌术后患者存在多种症状群,症状群越严重,患者的恐惧疾病进展水平越高,提示医护人员应做好肺癌术后患者症状群管理,以减轻患者对自身疾病进展或复发的恐惧心理,进而改善其生活质量。  相似文献   
986.
Purpose: The purpose of this study was to investigate the prognostic differences between patients with small-cell lung cancer (SCLC) with different chemosensitivity to first-line chemotherapy who developed brain metastasis (BM) as the first site of progression. Methods: Patients with a BM after first-line treatment in the Tianjin Cancer Hospital were retrospectively analyzed. According to the time-free interval (TFI) between the completion of first-line chemotherapy and the onset of the BM, the patients were divided into the chemo-sensitive group (TFI ≥ 90 days, n = 145) and the chemo-resistant group (TFI < 90 days, n = 97). The survival time, which was calculated from the diagnosis of the BM, was analyzed after the onset of brain metastasis (BM-OS). Survival curves were plotted using the Kaplan–Meier method, and differences between groups were compared using the log-rank test. Results: In total, the median BM-OS was 8.4 months. The median BM-OS in the chemo-sensitive group was 8.8 months, and it was 8.0 months in the chemo-resistant group (p = 0.538). In patients without extracranial progression (n = 193), the median BM-OSes in the chemo-sensitive and chemo-resistant groups were 9.4 months and 9.7 months, respectively (p = 0.947). In patients with extracranial progression (n = 49), the median BM-OSes in the chemo-sensitive and chemo-resistant groups were 5.4 months and 4.2 months, respectively (p = 0.161). Conclusions: After the development of a BM as the first site of progression following chemotherapy in patients with SCLC, the prognosis of chemo-sensitive patients was not necessarily superior to chemo-resistant patients, especially in patients without extracranial progression.  相似文献   
987.
BackgroundCancer-associated fibroblasts (CAFs) are vital components of gastric cancer (GC) microenvironments, which impact the aggressive characteristics of GC cells. The objective of this study is to evaluate the influence of High Mobility Group Box (HMGB) on CAF-related GC.MethodsThe tissues of 10 GC patients who underwent surgery the Sanya Central Hospital of Hainan Province from July 2018 to July 2019 were collected for the clinical study. Moreover, the GC cell lines, including MGC-803, AGS, and SGC-7901, were used in vitro experiment. We investigated the molecular mechanism of the miR-200b/HMGB3 axis in affecting the chemoresistance and epithelial-mesenchymal transition (EMT) of GC cells induced by CAFs. Cell transfection, Cell Counting Kit-8 (CCK-8), Transwell assay, western blot, enzyme-linked immunosorbent assay (ELISA), and other experiments were employed.ResultsWe found that miR-200b was down-regulated, yet HMGB3 was up-regulated in CAF-related GC. The CAFs markedly promoted cisplatin (CDDP) resistance, proliferation, invasion, migration, and EMT of GC cells. Gain-assay of miR-200b demonstrated that miR-200b inhibited the HMGB3 release from CAFs. In-vivo experiments confirmed that the growth and EMT of GC cells co-cultured with CAF-miR-200b were significantly reduced. Furthermore, CAFs enhanced the activation of ERK, JNK, and the Wnt/β-catenin pathways, and those pathways, as well as the malignant behaviors of GC cells, were obviously attenuated by miR-200b or HMGB3 silencing.ConclusionsCollectively, HMGB3 derived from CAFs is negatively regulated by miR-200b and promotes the malignant behaviors of GC cells.  相似文献   
988.
989.
It was known that mutations in the RT region were mainly related to nucleot(s)ide analogs resistance. Increasing studies indicated that RT mutations were related to advanced liver diseases (ALD) and had effects on HBV replication, but the distribution characteristics of mutations across RT region in the development of liver diseases and the effect of RT mutations on HBV replication were not fully clarified. HBV RT region was direct‐sequenced in 1473 chronic HBV‐infected patients. Mutation frequencies were analyzed to identify the specific mutations differing between groups classified by genotypes, loads of HBV DNA, or progression of liver diseases. In the range of rt145‐rt290, rt145, rt221, rt222, rt267, and rt271 were the genotype‐polymorphic sites, while rt238 was the genotype‐specific sites. Mutations at rt163, rt173, rt180, rt181, rt184, rt191, rt199, and rt214 were more frequent among patients with C‐genotype HBV, while those at rt220, rt225, rt226, rt269, and rt274 were more frequent among patients with B‐genotype HBV. RtM204V/I could reduce the HBV DNA loads while rtQ/L267H/R could increase the HBV DNA loads. RtV214A/E/I (OR 3.94, 95% CI 1.09 to 14.26) was an independent risk factor for advanced liver diseases. In summary, the hotspots of mutations were different between B and C genotypes. Besides the effect on the S region, RT mutations had effects on HBV replication by other unknown ways. RtV214A/E/I was found to be an independent risk factor for ALD, suggesting that mutations at rt214 site could be used as a potential virological marker for the liver disease progression.  相似文献   
990.
BACKGROUNDMills’ syndrome is an extremely rare degenerative motor neuron disorder first described by Mills in 1900, but its nosological status is still not clear. We aimed to analyze the clinical features of Mills’ syndrome.CASE SUMMARYHerein, we present 3 cases with similar features as those described in Mills’ original paper and review the related literature. Our patients showed middle- and older-age onset, with only upper motor neuron symptoms evident throughout the course of the disease. Spastic hemiplegia began in the lower extremity with a unique progressive pattern.CONCLUSIONWe consider that Mills’ syndrome is a unique entity of motor neuron disorder with an N-shaped progression. Clinicians should maintain a high index of suspicion for the diagnosis of Mills’ syndrome when the onset involves lower extremity paralysis without evidence of lower motor neuron or sensory involvement.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号